Key Segmentation
By Modality Type
- Multimodal
- Standalone
By Application
- Diagnosis & Screening
- Clinical Review
- Advanced Imaging
- Others
By End-User
- Hospitals
- Clinics
- Diagnostic & Imaging Centers
- Specialty Clinics
- Others
Regional Coverage:
North America
- US
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- ASEAN Countries
- Rest of Asia Pacific
Middle East & Africa
- UAE
- Saudi Arabia
- Qatar
- South Africa
- Rest of Middle East & Africa
Latin America
- Brazil
- Argentina
- Mexico
- Colombia
- Rest of Latin America
Available Customization
With the given market data SNS Insider offers customization as per the company's specific needs. The following customization options are available for the report:
- Detailed Volume Analysis
- Criss-Cross segment analysis (e.g. Type X Application)
- Competitive Product Benchmarking
- Geographic Analysis
- Additional countries in any of the regions
- Customized Data Representation
- Detailed analysis and profiling of additional market players
Frequently Asked Questions
Key players include Koninklijke Philips N.V., Siemens Healthineers AG, Hologic, Inc., GE HealthCare Technologies Inc., iCAD, Inc., Fujifilm Holdings Corporation, and Sectra AB, among other global medical imaging technology providers.
Continued innovation in AI-powered computer-aided detection tools and continued expansion of breast cancer screening programs across emerging markets represent the primary opportunities.
Growth is primarily driven by the rising prevalence of breast cancer worldwide combined with important technological developments including AI-powered diagnostic tools and digital tomosynthesis.
By Modality Type, Multimodal dominated the market with approximately 53.60% share in 2025, reflecting growing demand for integrated review of mammography, ultrasound, and MRI data.
North America dominated the market with approximately 54.60% share in 2025, driven by high awareness of breast cancer screening and substantial healthcare infrastructure investment.
